Developer docs
API playgroundTry for free, no card

Search company profiles

Vesalius Longevity Labs

Full company profile

uuid0009guw

Namestring
Vesalius Longevity Labs
Legal namestring
Vesalius, Inc.
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Vesalius Longevity Labs is a U.S.-based peptide therapeutics company founded in November 2024 and headquartered in Scottsdale, Arizona, that distributes a premium portfolio of peptide bioregulators under the Peptual brand through a B2Doctor ecosystem. Its product line spans multiple delivery modalities — injectables, transdermal patches, nasal sprays, oral peptides, and topical formulations — primarily sourced and manufactured in the U.S. at FDA-registered, cGMP-compliant facilities, and is positioned to address longevity, health optimization, anti-aging, and (through the Wisp partnership) women's reproductive and hormonal health including fertility and menopause. The company was co-founded by Dr. Matt Cook, a regenerative medicine authority, and Jennifer Benson, a Board Certified Integrative Holistic Health Practitioner; its leadership team includes CEO Dr. Pradeep Albert, CCO Timmi Stump, and COO Ted Stover, with an incoming CEO (Kevin Rabbitt) and reconstituted board set to take effect upon closing of the reverse takeover with Sweet Earth Holdings Corporation.

The business operates a hybrid GTM model: a global enterprise field-sales motion distributing product through an independent licensed healthcare provider network across North America, Europe, UAE, Asia Pacific, Latin America, and Australia, augmented by a channel-partner motion via Wisp, the largest pure-play women's telehealth provider in the U.S. (1.5M+ patients), for direct-to-consumer reach launching in early 2026. Revenue is generated through one-time product sales to providers and (via partners) to consumers; no direct pricing is publicly disclosed. The company is going public through a reverse takeover with Sweet Earth Holdings (CSE: SE), with the transaction expected to close in Q3 2025 and former Vesalius shareholders to hold approximately 80% of the combined entity, supported by approximately $19.4M in cumulative private placement proceeds. Marketing leverages wellness influencer endorsements (Ben Greenfield, Gary Brecka, Chris Bumstead, George Kittle), content marketing, Instagram, email, and PR, with the Scientific Advisory Board expanded in July 2025 to include Shane Bakker and Dean Henry.

Short descriptiontext

Vesalius Longevity Labs is a Scottsdale-based peptide therapeutics company that distributes its premium Peptual product line (injectables, patches, nasal sprays, oral peptides, topicals) through a global B2Doctor network of independent licensed providers and, via Wisp, women's telehealth, targeting longevity and women's health.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersScottsdale, United States
HQ citystring
Scottsdale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, longevity medicine, bioregulator products, regenerative peptides, wellness supplements
Industry2 codes
PRIMARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Peptide Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1B2Doctor Product Sales
TypeOne Time License
Description

Sale of peptide products and bioregulators through a global network of independent licensed healthcare providers. The company provides an end-to-end ecosystem including product fulfillment, with products distributed via doctor's offices and health professionals.

vesaliuslabs.com
2Consumer Product Sales (via partners)
TypeOne Time License
Description

Sale of peptide products directly to consumers through partnership channels, including telehealth providers like Wisp. Products include supplements and therapeutics targeting longevity, fertility, and menopause.

vesaliuslabs.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Peptual
Description

Premium line of peptides and bioregulators including injectables, patches, nasal sprays, oral peptides, and topical formulations.

vesaliuslabs.com
Core offering1 text field

Vesalius Longevity Labs develops and distributes premium peptide and bioregulator products under its Peptual product line, offered in multiple delivery formats including injectables, patches, nasal sprays, oral peptides, and topical formulations. Products are sold primarily to independent licensed healthcare providers through a global B2Doctor ecosystem with product fulfillment and education support, and to consumers via strategic telehealth partnerships (notably Wisp for women's health).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Peptide therapeutics market growing from $43.1B (2023) to $106B by 2033 at 10.8% CAGR
+2 more records
Product overview1 text field

Vesalius Longevity Labs operates as a peptide science company offering its Peptual branded product line—the company's core offering—which includes injectables, patches, nasal sprays, oral peptides, and topical formulations distributed through a global B2Doctor ecosystem of licensed healthcare providers. Through a strategic partnership with Wisp, the company is expanding into women's-specific peptide therapeutics (Women's Peptide Therapeutics sub-brand) targeting fertility and menopause, expected to launch in early 2026.

Product and service2 records
1Peptual Product Line
CategoryPeptide Therapeutics
Description

Peptual is Vesalius' flagship product line of premium peptides and bioregulators offered in multiple delivery formats (injectables, patches, nasal sprays, oral peptides, topical formulations). It is sold to and through independent licensed healthcare providers worldwide for use in longevity, health optimization, and anti-aging protocols, and is U.S.-sourced and manufactured in FDA-registered, cGMP-compliant facilities.

2Women's Peptide Therapeutics
CategoryWomen's Health Peptide Therapeutics
Description

A sub-brand under development that leverages the Peptual formulations (injectables, patches, nasal sprays, topical formulations) to create a dedicated women's health peptide portfolio targeting fertility and menopause, distributed via the Wisp telehealth platform serving over 1.5 million patients.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-09
Description

Strategic partnership between Vesalius Longevity Labs and Wisp, the largest pure play women's telehealth provider in the U.S., to develop and launch an exclusive range of peptide therapeutics designed for women's health needs including fertility and menopause. The collaboration leverages Vesalius' Peptual product line and Wisp's digital care infrastructure to address the gender gap in longevity care. Products are planned for launch in early 2026. The companies will also jointly evaluate emerging longevity AI platforms for potential integration and explore strategic investments in AI tools for personalized care and clinical decision support.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest pure-play women's telehealth provider in the U.S. serving 1.5M+ patients. Partnered with Vesalius to launch women's peptide therapeutics for fertility and menopause; comparable in telehealth infrastructure, women's health focus, and consumer prescription delivery model.

TypeDirect peer
Description

Telehealth clinic specializing in hormone replacement, peptide therapy, and wellness treatments prescribed by physicians and shipped directly to patients. Closely aligned with Vesalius' prescriber-mediated peptide distribution model and longevity focus.

TypeBroad incumbent
Description

Global pharmaceutical leader whose tirzepatide franchises (Mounjaro, Zepbound) are peptide-based and have driven mainstream validation of peptide therapeutics. Sets the public-market benchmark for peptide therapeutic value capture, even though the products and indications differ from Vesalius' longevity focus.

TypeDirect peer
Description

Direct-to-consumer telehealth platform offering hormone optimization, peptide therapy, and longevity treatments prescribed by licensed physicians. Directly comparable to Vesalius' B2Doctor + telehealth model and overlapping product categories (longevity peptides, hormone-related therapeutics).

TypeDirect peer
Description

Online men's health and longevity platform offering hormone therapy, peptides, and performance optimization through licensed providers. Comparable consumer-prescriber model and overlapping peptide portfolio targeting similar affluent, health-optimization customer segments.

TypeBroad incumbent
Description

Long-established direct-to-consumer supplements brand with a strong longevity clinical franchise, including hormone and peptide-adjacent products. Comparable customer demographic and longevity/health-optimization positioning, but a much broader portfolio spanning vitamins, supplements, and diagnostics.

TypeBroad incumbent
Description

Large, well-established supplements and health-optimization brand offering practitioner-grade nutritional supplements, including some peptide-related formulations. Comparable premium supplement positioning, practitioner channel, and longevity/healthspan audience, though broader in scope than Vesalius' peptide focus.

TypeEmerging player
Description

Women's midlife and menopause-focused virtual care clinic offering hormone therapy and wellness programs. Directly comparable to the women's health sub-brand Vesalius is launching with Wisp, and a relevant emerging competitor in the same demographic and indication space.

TypeDirect peer
Description

Medical-grade hormone optimization and peptide therapy company with a large network of certified providers. Comparable B2Doctor commercial model, broad provider education program, and adjacency in wellness/restorative therapy markets.

TypeDirect peer
Description

Telehealth longevity clinic offering prescription peptides, NAD+, and anti-aging therapies to consumers nationwide. Most direct overlap with Vesalius' Peptual line on the consumer-facing peptide prescribing and distribution side.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vesalius Longevity Labs

Peptide Therapeuticsvesaliuslabs.com

Vesalius Longevity Labs is a Scottsdale-based peptide therapeutics company that distributes its premium Peptual product line (injectables, patches, nasal sprays, oral peptides, topicals) through a global B2Doctor network of independent licensed providers and, via Wisp, women's telehealth, targeting longevity and women's health.

What Vesalius Longevity Labs does

Vesalius Longevity Labs is a U.S.-based peptide therapeutics company founded in November 2024 and headquartered in Scottsdale, Arizona, that distributes a premium portfolio of peptide bioregulators under the Peptual brand through a B2Doctor ecosystem. Its product line spans multiple delivery modalities — injectables, transdermal patches, nasal sprays, oral peptides, and topical formulations — primarily sourced and manufactured in the U.S. at FDA-registered, cGMP-compliant facilities, and is positioned to address longevity, health optimization, anti-aging, and (through the Wisp partnership) women's reproductive and hormonal health including fertility and menopause. The company was co-founded by Dr. Matt Cook, a regenerative medicine authority, and Jennifer Benson, a Board Certified Integrative Holistic Health Practitioner; its leadership team includes CEO Dr. Pradeep Albert, CCO Timmi Stump, and COO Ted Stover, with an incoming CEO (Kevin Rabbitt) and reconstituted board set to take effect upon closing of the reverse takeover with Sweet Earth Holdings Corporation.

The business operates a hybrid GTM model: a global enterprise field-sales motion distributing product through an independent licensed healthcare provider network across North America, Europe, UAE, Asia Pacific, Latin America, and Australia, augmented by a channel-partner motion via Wisp, the largest pure-play women's telehealth provider in the U.S. (1.5M+ patients), for direct-to-consumer reach launching in early 2026. Revenue is generated through one-time product sales to providers and (via partners) to consumers; no direct pricing is publicly disclosed. The company is going public through a reverse takeover with Sweet Earth Holdings (CSE: SE), with the transaction expected to close in Q3 2025 and former Vesalius shareholders to hold approximately 80% of the combined entity, supported by approximately $19.4M in cumulative private placement proceeds. Marketing leverages wellness influencer endorsements (Ben Greenfield, Gary Brecka, Chris Bumstead, George Kittle), content marketing, Instagram, email, and PR, with the Scientific Advisory Board expanded in July 2025 to include Shane Bakker and Dean Henry.

Vesalius Longevity Labs firmographics

Firmographics
Name
Vesalius Longevity Labs
Legal name
Vesalius, Inc.
Website
https://vesaliuslabs.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
11–50 employees
Short description
Vesalius Longevity Labs is a Scottsdale-based peptide therapeutics company that distributes its premium Peptual product line (injectables, patches, nasal sprays, oral peptides, topicals) through a global B2Doctor network of independent licensed providers and, via Wisp, women's telehealth, targeting longevity and women's health.
Ownership category
akta.pro rank

Vesalius Longevity Labs industry classification

Industry
Product category
Peptide Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRADAGAE
Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity)
SECONDARYCRADAGAK
Women’s Health Supplements (Prenatal, Menopause, Hormonal)

Keywords

  • Peptide therapeutics
  • Longevity medicine
  • Bioregulator products
  • Regenerative peptides
  • Wellness supplements

Where Vesalius Longevity Labs is headquartered

Location

Headquarters

HQ city
Scottsdale
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vesalius Longevity Labs business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. B2Doctor Product Sales: Sale of peptide products and bioregulators through a global network of independent licensed healthcare providers. The company provides an end-to-end ecosystem including product fulfillment, with products distributed via doctor's offices and health professionals.
  2. Consumer Product Sales (via partners): Sale of peptide products directly to consumers through partnership channels, including telehealth providers like Wisp. Products include supplements and therapeutics targeting longevity, fertility, and menopause.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Vesalius Longevity Labs product offering

Product offering

Core offering

Vesalius Longevity Labs develops and distributes premium peptide and bioregulator products under its Peptual product line, offered in multiple delivery formats including injectables, patches, nasal sprays, oral peptides, and topical formulations. Products are sold primarily to independent licensed healthcare providers through a global B2Doctor ecosystem with product fulfillment and education support, and to consumers via strategic telehealth partnerships (notably Wisp for women's health).

Product overview

Vesalius Longevity Labs operates as a peptide science company offering its Peptual branded product line—the company's core offering—which includes injectables, patches, nasal sprays, oral peptides, and topical formulations distributed through a global B2Doctor ecosystem of licensed healthcare providers. Through a strategic partnership with Wisp, the company is expanding into women's-specific peptide therapeutics (Women's Peptide Therapeutics sub-brand) targeting fertility and menopause, expected to launch in early 2026.

Differentiator

Problem solved

Functional benefit

Brands

  • Peptual: Premium line of peptides and bioregulators including injectables, patches, nasal sprays, oral peptides, and topical formulations.

Products and services

  • Peptual Product Line Peptual is Vesalius' flagship product line of premium peptides and bioregulators offered in multiple delivery formats (injectables, patches, nasal sprays, oral peptides, topical formulations). It is sold to and through independent licensed healthcare providers worldwide for use in longevity, health optimization, and anti-aging protocols, and is U.S.-sourced and manufactured in FDA-registered, cGMP-compliant facilities.
  • Women's Peptide Therapeutics A sub-brand under development that leverages the Peptual formulations (injectables, patches, nasal sprays, topical formulations) to create a dedicated women's health peptide portfolio targeting fertility and menopause, distributed via the Wisp telehealth platform serving over 1.5 million patients.

Quantifiable outcome

  • Peptide therapeutics market growing from $43.1B (2023) to $106B by 2033 at 10.8% CAGR
  • +2 more outcomes

Companies that use Vesalius Longevity Labs

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Vesalius Longevity Labs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vesalius Longevity Labs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • WispcoreStrategic or Co-development Partner · 9 October 2025Strategic partnership between Vesalius Longevity Labs and Wisp, the largest pure play women's telehealth provider in the U.S., to develop and launch an exclusive range of peptide therapeutics designed for women's health needs including fertility and menopause. The collaboration leverages Vesalius' Peptual product line and Wisp's digital care infrastructure to address the gender gap in longevity care. Products are planned for launch in early 2026. The companies will also jointly evaluate emerging longevity AI platforms for potential integration and explore strategic investments in AI tools for personalized care and clinical decision support.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Vesalius Longevity Labs competitors and assessment

Company assessment

Direct peers

  • Wisp: Largest pure-play women's telehealth provider in the U.S. serving 1.5M+ patients. Partnered with Vesalius to launch women's peptide therapeutics for fertility and menopause; comparable in telehealth infrastructure, women's health focus, and consumer prescription delivery model.
  • Defy Medical: Telehealth clinic specializing in hormone replacement, peptide therapy, and wellness treatments prescribed by physicians and shipped directly to patients. Closely aligned with Vesalius' prescriber-mediated peptide distribution model and longevity focus.
  • Hone Health: Direct-to-consumer telehealth platform offering hormone optimization, peptide therapy, and longevity treatments prescribed by licensed physicians. Directly comparable to Vesalius' B2Doctor + telehealth model and overlapping product categories (longevity peptides, hormone-related therapeutics).
  • Marek Health: Online men's health and longevity platform offering hormone therapy, peptides, and performance optimization through licensed providers. Comparable consumer-prescriber model and overlapping peptide portfolio targeting similar affluent, health-optimization customer segments.
  • BioTE Medical: Medical-grade hormone optimization and peptide therapy company with a large network of certified providers. Comparable B2Doctor commercial model, broad provider education program, and adjacency in wellness/restorative therapy markets.
  • AgelessRx: Telehealth longevity clinic offering prescription peptides, NAD+, and anti-aging therapies to consumers nationwide. Most direct overlap with Vesalius' Peptual line on the consumer-facing peptide prescribing and distribution side.

Broad incumbents

  • Eli Lilly (Mounjaro / Zepbound): Global pharmaceutical leader whose tirzepatide franchises (Mounjaro, Zepbound) are peptide-based and have driven mainstream validation of peptide therapeutics. Sets the public-market benchmark for peptide therapeutic value capture, even though the products and indications differ from Vesalius' longevity focus.
  • Life Extension: Long-established direct-to-consumer supplements brand with a strong longevity clinical franchise, including hormone and peptide-adjacent products. Comparable customer demographic and longevity/health-optimization positioning, but a much broader portfolio spanning vitamins, supplements, and diagnostics.
  • Thorne: Large, well-established supplements and health-optimization brand offering practitioner-grade nutritional supplements, including some peptide-related formulations. Comparable premium supplement positioning, practitioner channel, and longevity/healthspan audience, though broader in scope than Vesalius' peptide focus.

Emerging players

  • Midi Health: Women's midlife and menopause-focused virtual care clinic offering hormone therapy and wellness programs. Directly comparable to the women's health sub-brand Vesalius is launching with Wisp, and a relevant emerging competitor in the same demographic and indication space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Vesalius Longevity Labs social profiles

Digital presence

Vesalius Longevity Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vesalius Longevity Labs leadership team

Management profile

Number of profiles

Profiles6 records

Vesalius Longevity Labs subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vesalius Longevity Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vesalius Longevity Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vesalius Longevity Labs

What does Vesalius Longevity Labs do?

Vesalius Longevity Labs develops and distributes premium peptide and bioregulator products under its Peptual product line, offered in multiple delivery formats including injectables, patches, nasal sprays, oral peptides, and topical formulations. Products are sold primarily to independent licensed healthcare providers through a global B2Doctor ecosystem with product fulfillment and education support, and to consumers via strategic telehealth partnerships (notably Wisp for women's health).

Is Vesalius Longevity Labs a public or private company?

Vesalius Longevity Labs is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vesalius Longevity Labs founded?

Vesalius Longevity Labs was founded in 2024. It employs 11 to 50 people.

Where is Vesalius Longevity Labs based?

Vesalius Longevity Labs is headquartered in Scottsdale, United States, in the North America region.

How does Vesalius Longevity Labs make money?

Two revenue lines are on record. B2Doctor Product Sales are the primary driver. The others are consumer Product Sales (via partners).

Who are Vesalius Longevity Labs's main competitors?

Direct peers on record are Wisp, Defy Medical, Hone Health, Marek Health, BioTE Medical and AgelessRx. Broad incumbents are Eli Lilly (Mounjaro / Zepbound), Life Extension and Thorne. Midi Health is listed as an emerging player.

Does Vesalius Longevity Labs have an API?

No public API is recorded for Vesalius Longevity Labs.

What industry is Vesalius Longevity Labs in?

Vesalius Longevity Labs's product category is Peptide Therapeutics. Its primary akta.pro industry code is CRADAGAE, Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity), with a secondary code of CRADAGAK, Women’s Health Supplements (Prenatal, Menopause, Hormonal). Its NAICS code is 325414 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NewsfileVesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand DevelopmentVesalius Longevity Labs appointed Harvey Spevak as Chairman, effective November 13, 2026, following a US$6.5 million financing led by him. The company's peptide therapeutics market is projected to reach US$295 billion by 2033, and it has an exclusive manufacturing partnership with Celularity.AktienVesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand DevelopmentVesalius Longevity Labs appointed Harvey Spevak as chairman, effective November 13, 2026, following a US$6.5 million financing led by him. The appointment follows a US$6.5 million financing led by Mr. Spevak, who brings a globally recognized leader in the wellness space to Vesalius as interest in longevity and proactive health continues to accelerate.NewsfileVesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol "VLAB"Vesalius Longevity Labs will begin trading on the Canadian Securities Exchange under the symbol VLAB on November 12, 2026. The company, a longevity science platform, operates a B2Doctor2Consumer ecosystem and manufactures peptide APIs under its Peptual brand. The listing statement was filed on SEDAR+ on November 9, 2026.AthletechnewsEquinox Chair Leads $6.5M Financing Round for Vesalius Longevity LabsVesalius Longevity Labs raised $6.5 million in a financing round led by an investor group organized by Harvey Spevak, chairman of Equinox Group. The company sold about 6.2 million units at $1.05 each, with proceeds to expand its provider network and enter new markets. The investment includes warrants for additional shares.NewswireVesalius Longevity Labs Announces Commencement of Trading on the Canadian Securities Exchange Under the Symbol "VLAB"Vesalius Longevity Labs will commence trading on the Canadian Securities Exchange under the symbol VLAB on November 12, 2026. The company, formerly Sweet Earth Holdings, operates a B2Doctor2Consumer ecosystem for peptide therapeutics and biologics. The listing statement was filed on SEDAR+ on November 9, 2026.YahooVesalius Longevity Labs Closes Strategic Financing of US$6.5 Million, Led by Investor Group Organized by Harvey SpevakVesalius Longevity Labs completed a private placement of 6,190,475 units at $1.05 each, raising $6.5 million gross. The financing was led by an investor group organized by Harvey Spevak, who will partner to expand sales and enter new markets.NewswireVesalius Longevity Labs Closes Strategic Financing of US$6.5 Million, Led by Investor Group Organized by Harvey SpevakVesalius Longevity Labs closed a non-brokered private placement of 6,190,475 units at $1.05 each, raising gross proceeds of $6,499,998.75. The financing was led by an investor group organized by Harvey Spevak, chairman of Equinox Group. The company will use the funds to expand its sales team and enter new markets.TradingViewCelularity Signs Exclusive U.S. Peptide API Manufacturing Collaboration with VesaliusCelularity signed an exclusive collaboration with Vesalius to purify, process, test, and manufacture Peptual-branded peptide APIs at its New Jersey facility. The deal uses supplier-provided bulk peptide material and aims for cGMP processes, but commercial supply to U.S. compounding pharmacies is uncertain and not authorized by the agreement alone.Business Wire BlogCelularity and Vesalius Longevity Labs Sign Exclusive Collaboration for Peptual® Peptide APIs Manufactured in the United StatesCelularity and Vesalius Longevity Labs signed an exclusive agreement for Celularity to manufacture Vesalius's Peptual peptide APIs in the U.S. The collaboration will use Celularity's Florham Park facility for downstream processing and cGMP-compliant manufacturing. The parties intend to supply eligible APIs to U.S. compounding pharmacies if the FDA adds them to its bulk drug list.NewswireVesalius Announces Closing of Reverse Takeover TransactionVesalius Longevity Labs closed its reverse takeover, trading under the symbol VLAB on the Canadian Securities Exchange. The company issued 100,828,947 shares outstanding, with former Vesalius Canada shareholders receiving 41.86% and SPV shareholders 29.91% on a fully diluted basis. Trading is expected to resume under the new symbol.